These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28783771)

  • 21. Comparative effectiveness of warfarin and new anticoagulants.
    Reiffel JA
    Ann Intern Med; 2013 Apr; 158(8):637. PubMed ID: 23588758
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative effectiveness of warfarin and new anticoagulants.
    Trowbridge RL; Smith KE
    Ann Intern Med; 2013 Apr; 158(8):636-7. PubMed ID: 23588757
    [No Abstract]   [Full Text] [Related]  

  • 23. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
    Saraf K; Morris PD; Garg P; Sheridan P; Storey R
    Postgrad Med J; 2014 Sep; 90(1067):520-8. PubMed ID: 25085900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.
    Hurley C; Dai S; Sobieraj DM
    Int J Cardiol; 2015 Aug; 192():1-2. PubMed ID: 25981569
    [No Abstract]   [Full Text] [Related]  

  • 25. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing paradigm.
    Chaudhari D; Bhuriya R; Arora R
    Am J Ther; 2011 Jan; 18(1):e1-e11. PubMed ID: 20460986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of direct factor Xa inhibitors compared to warfarin in preventing stroke in adults with non-valvular atrial fibrillation: a systematic review protocol.
    Rasmussen KL; Hampton MD
    JBI Database System Rev Implement Rep; 2016 Jun; 14(6):69-77. PubMed ID: 27532651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
    Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
    Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal Function in Atrial Fibrillation: A Multifaceted Dilemma.
    Hijazi Z; Wallentin L
    Circulation; 2016 Jul; 134(1):48-51. PubMed ID: 27358436
    [No Abstract]   [Full Text] [Related]  

  • 31. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
    Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
    Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing patient preferences for switching from warfarin to direct oral anticoagulants.
    Wright JN; Vazquez SR; Kim K; Jones AE; Witt DM
    J Thromb Thrombolysis; 2019 Nov; 48(4):596-602. PubMed ID: 31273515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trials and tribulations.
    Greaves M
    J Thromb Haemost; 2014 Jun; 12(6):822-3. PubMed ID: 24655890
    [No Abstract]   [Full Text] [Related]  

  • 34. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Stroke Associated with Atrial Fibrillation and Novel Oral Anticoagulants (NOACs)].
    Ieko M
    Rinsho Byori; 2014 Oct; 62(10):948-57. PubMed ID: 27526540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes associated with a change in clinical practice to alleviate emotional harm related to venous thromboembolism.
    Jones AE; Feehan M; Fleming R; Johnson SA; Witt DM
    Thromb Res; 2019 Aug; 180():29-31. PubMed ID: 31176947
    [No Abstract]   [Full Text] [Related]  

  • 38. Terminated.
    Rosendaal FR; Reitsma PH
    J Thromb Haemost; 2014 Jun; 12(6):813. PubMed ID: 24916285
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of Patients With Atrial Fibrillation.
    Beaser AD; Cifu AS
    JAMA; 2019 Mar; 321(11):1100-1101. PubMed ID: 30874742
    [No Abstract]   [Full Text] [Related]  

  • 40. Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy.
    Huynh K
    Nat Rev Cardiol; 2015 May; 12(5):256. PubMed ID: 25824520
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.